Basic and Clinical studies of Ciprofloxacin (CPFX) in oral and maxillofacial surgery

Abstract

Basic and clinical studies were carried out to evaluate the usefulness of Ciprofloxacin (CPFX) in the field of oral and maxillofacial surgery, and the following results were obtained.
1) The MIC₅₀ of CPFX against 68 Streptococcus sp. clinically isolated was 1.56μg/ml and the MIC₈₀ was 3.13μg/ml thereto. Both of the MIC₅₀ and MIC₈₀ of CPFX against 7 Staphyrococcus sp. were 0.78μg/ml.
2) Oral tissues in rabbits showed their peaks at 1 hour after oral administration of 20mg/kg. The levels in oral soft tissues were superior to those in serum. Especially, in salivary gland and gingiva, higher levels were found among soft tissues. Jaw bone levels, however, were inferior to serum levels. The penetration of CPFX into oral tissues in human was determined 1.5 to 7 hours after oral administration of 200mg. The levels in gingiva ranged from 0.28 to 2.09μg/g (2-4.5hours) and were almost the same as those in serum. Most of the levels of jaw bone, however, were inferior to those of serum.
3) With administration of CPFX at a daily dose of 600mg into 27 odontogenic infection cases, the clinical efficacy rate was 85.2% (23/27) .
4) It was considered that CPFX was effective in the treatment of mild and moderate odontogenic infections.